IngredientsNori (Japanese: 海苔) is a dried edible seaweed used in Japanese cuisine, usually made from species of the red algae genus Pyropia, including P. yezoensis and P. tenera. The principal commercially cultivated species, Neopyropia yezoensis (formally Pyropia yezoensis), is a red macroalga (Rhodophyta) belonging to the order Bangiales and class Bangiophyceae. This species was previously known as Porphyra yezoensis.
In 2020, Brodie and Yang reclassified Neopyropia as a new genus within the Bangiales, based on molecular phylogenetic analyses that distinguished it from Pyropia and other related genera. Species of Pyropia belonging to the order Bangiales include P. columbina, P. crassa, and P. haitanensis, while Neopyropia includes species such as N. yezoensis, N. tenera, and N. leucosticta. Susabi-nori (Pyropia yezoensis) is a species of red algae in the family Bangiaceae.
Within the genus Pyropia, multiple species are used for nori (edible seaweed), with Pyropia yezoensis and P. haitanensis being most popular. It is a two-billion-dollar industry with most major growers located in China, Korea, and Japan. In Korean cuisine, the same product is known as gim (김); in Chinese, as haitai (海苔) or zicai (紫菜); and in Wales and Ireland, the related species is consumed as laverbread. The red algae genus is also consumed in Korean cuisine as gim (김), in Chinese cuisine as haitai (海苔) or zicai (紫菜), and in Wales and Ireland as laverbread.
Key identifying features include a color that is deep green to reddish-purple, often appearing darker than other seaweeds; a smooth and delicate texture with a slight sheen; and flat blades that can grow up to 30 cm long, attached to rocky substrates. Nori thrives in cool waters, typically in temperatures ranging from 8°C to 16°C, and prefers rocky substrates, often found clinging to rocks in intertidal zones and submerged areas where sufficient light penetrates the water.
Nori grows as a very thin, flat, reddish blade, and is found in most temperate intertidal zones around the world, illustrated by its history of being eaten by the indigenous peoples of northwest America and Canada, Hawaii, and New Zealand.
Nori is processed and sold in several commercial forms:
Farming takes place in the sea where the Pyropia plants grow attached to nets suspended at the sea surface and where the farmers operate from boats. The plants grow rapidly, requiring approximately 45 days from "seeding" until the first harvest. In Japan, more than 600 square kilometres of coastal waters are given to producing 350,000 tonnes of nori, worth more than a billion dollars. China produces approximately a third of this amount.
Marine red algae of the order Bangiales (Rhodophyta) such as Pyropia and Porphyra (laver) have been important seafoods in East and Southeast Asia for thousands of years. Lavers are also harvested in New Zealand, Chile, Wales, and Pacific North America. In Japan, the aquaculture of Bangiales seaweeds (so-called 'nori') started three hundred years ago, and many different species have been cultivated. Currently, susabi-nori (Pyropia yezoensis) is the highly valued seaweed crop in East Asia, as well as in Japan.
Nori — despite not being cultivated by humans until the 1600s — has been popular since the pre-modern era in Japan, having been used as currency, offerings at shrines, and food since the 700s. In Japan, seaweed consumption dates back over 2,000 years, and though originally reserved for the aristocracy, nori became a staple in sushi by the 17th century.
In Japan, seaweed was used for tax payments and given as gifts to the imperial court. It was also presented as a food offering in Shintō religious rituals. During the Kamakura period, a significant shift occurred in Japanese food culture. The extravagant eating habits of court nobles and aristocrats led to the development of frugal and perfected vegetarian cuisine. Nori, valued in Buddhist culinary traditions incorporating traditional Japanese ingredients, played a crucial role in this transformation.
It was only in the 18th century that the process for drying nori into sheets was invented, derived from that of the papermakers in Edo, or Tokyo. This sheet-drying technique transformed nori from a fresh or loosely dried commodity into the standardized product now recognized globally.
Chinese records as far back as the 27th century BC describe seaweed as a luxury food for royalty and document its medicinal uses, such as treating migraines and infections. The use of seaweed as a food source has been traced back to the fourth century in Japan and the sixth century in China, where it was served as a rare delicacy to honored guests and emperors. In Chinese tradition, nori-type algae (zicai) have been incorporated into soups and medicinal preparations for centuries, with early texts attributing general strengthening and tonic properties to their consumption.
Korea, too, has a rich history of seaweed consumption, with mentions dating to the 13th century. Koreans consider miyeokguk (seaweed soup) a healthful dish, often consumed after childbirth or on birthdays. In Korea, seaweed soup has traditionally been eaten as a birthday breakfast and served to women after childbirth to help with recovery and milk production.
Nori is found in most temperate intertidal zones around the world, illustrated by its history of being eaten by the indigenous peoples of northwest America and Canada, Hawaii, and New Zealand. In Wales and Ireland, the closely related Porphyra umbilicalis has historically been consumed as laverbread, a traditional dish made by boiling and pureeing laver seaweed, which has been part of the diet in coastal Wales for centuries.
Seaweeds are a good source of nutrients such as proteins, vitamins, minerals, and dietary fiber. Polyphenols, polysaccharides, and sterols, as well as other bioactive molecules, are mainly responsible for the healthy properties associated with seaweed.
The protein content of nori ranges from 11% to 32% of dry weight, making it valuable for diverse dietary preferences, including vegetarian and vegan diets. Red seaweeds, which include nori, have higher protein levels compared to brown seaweeds. Aspartic and glutamic acids are the most abundant amino acids.
Nori is particularly rich in vitamin B12, iodine, polyphenols, vitamin C, manganese, vitamin B7 (biotin), vitamin B9 (folate), carotenoids, vitamin B2 (riboflavin), EPA and DHA, copper, and vitamin A. If seaweeds are compared to terrestrial plants, they have a higher proportion of essential fatty acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
Porphyran is the most pharmacologically studied unique polysaccharide derived from nori. Neopyropia yezoensis is valued worldwide for its rich bioactive constituents, including polysaccharides, porphyrans, pigments, phenolic compounds, phycobiliproteins, polyunsaturated fatty acids, mycosporine-like amino acids, and both synthetic and recombinant peptides. Porphyran is a sulfated galactan found specifically in the cell walls of Pyropia/Neopyropia species.
The usefulness of naturally occurring polysaccharides in the food, agricultural, and medical fields has been well documented. In particular, indigestible polysaccharides as dietary fibers provide various beneficial effects, such as lowering of blood cholesterol level and blood pressure, as well as protective effects against infectious and inflammatory diseases. Some polysaccharides are even known to be potent immune modulators.
In terms of mechanism, porphyran, a sulfated polysaccharide found in red algae of the genus Porphyra, triggers a cascade of cellular signaling. It stimulates the phosphorylation of specific proteins that activate the NF-κB pathway, which induces the production of cytokines such as IL-6, TNF-α, and IFN-γ, all involved in coordinating the immune response.
Regarding lipid metabolism, porphyran supplementation was shown to significantly decrease apolipoprotein B100 secretion in HepG2 cells through a mechanism partially associated with the suppression of cellular lipid synthesis, representing the first study to elucidate the mechanism for the hypolipidemic effect of porphyran.
Studies also suggest a prebiotic role. Porphyrans have been found to regulate the gut microbiota during the treatment of metabolic syndrome. The prebiotic effect of N. yezoensis porphyran through modulation of the gut microbiota has also been investigated.
Studies have indicated that protein hydrolysates and peptides derived from N. yezoensis with low molecular weights and aromatic and/or hydrophobic amino acids contribute significantly to these diverse bioactivities.
Among the most studied peptides are those with angiotensin-converting enzyme (ACE) inhibitory activity. Nori-peptides have a potent angiotensin I converting enzyme (ACE) inhibitory activity. They have been fractionated from red alga Porphyra yezoensis (Nori) using ion-exchange and gel-filtration. Previous reports showed that the amino acid sequences of ACE inhibitory Nori-peptides were Ile-Tyr, Met-Lys-Tyr, Ala-Lys-Thr-Ser-Tyr, and Leu-Arg-Tyr, and 200 mg/kg of Nori-peptides induced a significant blood pressure reduction in spontaneously hypertensive rats.
Water-soluble proteins present in Pyropia species include phycoerythrin, phycocyanin, allophycocyanin, and ribulose 1,5-bisphosphate carboxylase/oxygenase (Rubisco). Phycoerythrin and related phycobiliproteins are the principal light-harvesting pigments of red algae and have themselves demonstrated antioxidant properties in vitro. Sulfated polysaccharides, oligosaccharides, mycosporine-like amino acids (MAAs), phycoerythrin, bromophenols, phlorotannin, and terpenoid-derived metabolites have demonstrated antioxidant capacity through radical scavenging, metal chelation, and modulation of endogenous antioxidants.
Polyphenols, polysaccharides, and sterols, as well as other bioactive molecules, are mainly responsible for the healthy properties associated with seaweed. Nori also contains meaningful concentrations of fat-soluble vitamins. Nori and other red algae carry ample amounts of vitamin A; 100 g of fresh, raw nori contains approximately 5,202 IU, or 1,734% of daily recommended levels of vitamin A. The B-vitamin content is likewise notable, with nori being among the rare plant-based sources of cobalamin (vitamin B12), a topic addressed in detail in the clinical evidence section below.
Nori composes sugars and fats in low percentages but has a high content of minerals and vitamins, with significant amounts of vitamins A, vitamin C, and B-complex groups, and minerals like iodine, manganese, phosphorus, and iron. Measured iodine concentrations of 5.0 µg/g have been reported for nori in human feeding studies, which is much lower than the 3,522 µg/g observed in Kombu. The highest copper concentration among common edible seaweeds was observed in nori, at 3.36 µg/g.
If seaweeds are compared to terrestrial plants, they have a higher proportion of essential fatty acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Nori's total fat content is low overall, with seaweed fat levels ranging from 1 to 2% of dry weight, but a notable fraction of this fat is composed of these long-chain omega-3 polyunsaturated fatty acids.
Mycosporine-like amino acids are UV-absorbing compounds found in high concentrations in intertidal and shallow-water algae like Pyropia species. These mycosporine-like amino acids are among the recognized bioactive constituents of Neopyropia yezoensis. In vitro, they act as natural sunscreens and antioxidants, though no confirmed human clinical evidence currently exists for their therapeutic application from nori consumption.
Mechanism: Peptides derived from Pyropia yezoensis have been shown to have ACE I inhibitory activity and hypotensive effects. Porphyran, a main constituent of Pyropia yezoensis, potentially has antioxidant activity, and it is likely that these unique biologically active compounds of nori play an important role in reducing blood pressure.
Early human/clinical data: Nori-peptides have a potent angiotensin I converting enzyme (ACE) inhibitory activity. A study by Saito and colleagues published in the American Journal of Hypertension (2002) examined the antihypertensive effect of Nori-peptides derived from Porphyra yezoensis in hypertensive patients, establishing early human-level evidence for ACE-inhibitory activity.
Intervention study in children: A 2021 study published in the Journal of Epidemiology investigated whether dietary nori intake affects blood pressure. Researchers conducted an intervention study in children aged 4 to 5 years attending a preschool in Aichi Prefecture, Japan, in 2010. Among 99 students, 89 (89.9%) were enrolled. Nori (dried laver) was used as a dietary intervention. Children in the intervention group were asked to consume 1.76 grams per day of roasted nori in addition to standard meals for 10 weeks. Children in the control group consumed their usual diet. Changes in systolic (SBP) and diastolic blood pressure (DBP) were compared between 55 children in the intervention group and 26 in the control group after adjustment for SBP and DBP before the intervention. Changes in SBP were −8.29 mm Hg in the intervention group and +0.50 mm Hg in the control group. The authors noted that the causative factor could not be definitively identified. This was a single-center interventional study in a pediatric population, and results cannot be directly extrapolated to adults.
Evidence strength: The antihypertensive ACE-inhibitory peptide data are well characterized in vitro and in animal models. Human clinical evidence is limited — primarily one pediatric interventional study and early-phase human trials — and lacks large, randomized controlled trials in adult populations. Limited human trials suggest modest but clinically relevant improvements in blood pressure, glycemic control, lipid profiles, and body-weight-related outcomes, primarily using whole algal biomass or extracts. Japan has designated Neopyropia yezoensis (formerly Pyropia yezoensis) as a Food for Specified Health Uses (FOSHU), based on demonstrated antihypertensive effects.
The question of whether nori provides bioavailable vitamin B12 has been scientifically contested for decades. The evidence base has evolved significantly.
Contradictory early findings: It had been reported that the B12 nutritional status of vegetarian children deteriorated, as estimated by the hematological index (mean corpuscular volume), after they consumed dried nori as a source of cobalamin. Such a discrepancy between raw and dried nori led to investigation of whether cobalamin in dried nori had different properties from that in raw nori. The urinary methylmalonic acid excretion increased when human female volunteers were given 40 g of dried nori daily during the test period. An earlier observational study, however, found that vegans consuming nori and/or Chlorella seaweeds had serum vitamin B12 concentrations twice as high as those not using these seaweeds.
2024 Randomized Controlled Trial: A landmark study by Huang and colleagues, published in the European Journal of Nutrition (2024), provided the most rigorous human evidence to date. The study design was an open-label, parallel, dose-response randomized controlled trial. Thirty vegetarians were assigned to a control (no nori), low-dose (5 g nori, aiming to provide 2.4 µg vitamin B12 per day), or high-dose (8 g nori, aiming to provide 4 µg vitamin B12 per day) group. The primary outcome was changes in vitamin B12 status as measured by serum vitamin B12, holotranscobalamin (holoTC), homocysteine (Hcy), and methylmalonic acid (MMA), and a combined score of these four markers (4cB12 score) during the four-week intervention.
Consuming 5 g of nori per day for 4 weeks significantly improved vitamin B12 status in vegetarians. A higher dose (8 g) may not confer additional benefits. The consumption of 5 g nori per day for four weeks was linked to a significant improvement in serum vitamin B12 levels. These findings indicate that nori contains bioavailable B12 and not an inhibitory B12 analog.
Evidence strength: This 2024 RCT represents a meaningful advance, but the trial was small (30 participants), of short duration (4 weeks), and conducted in a Taiwanese population. The Academy of Nutrition and Dietetics considers nori an unreliable source of B12 for vegans. The current consensus among major Western dietetic bodies is that nori should not be considered a primary or reliable B12 source, though the 2024 RCT evidence challenges prior assumptions for roasted purple laver specifically.
Mechanism and in vitro data: Polyphenols, polysaccharides, and sterols, as well as other bioactive molecules, are mainly responsible for the healthy properties associated with seaweed. Antioxidant, anti-inflammatory, anti-cancer, and anti-diabetic properties are attributed to these compounds.
Porphyran isolated from nori has been shown in vitro to scavenge free radicals. Porphyran from discolored nori showed scavenging activity toward superoxide anion and hydroxyl radicals. The reported structures that act as antioxidants include chitosan, pectic polysaccharides, glucans, mannoproteins, alginates, fucoidans, and many others; structural features linked to the antioxidant action include the polysaccharide charge, molecular weight, and the occurrence of non-carbohydrate substituents.
Evidence strength: The antioxidant evidence for nori constituents is predominantly in vitro and in animal models. No standalone clinical trials in humans have isolated and tested antioxidant endpoints from nori consumption specifically. The broader category of seaweed antioxidants is an active area of preclinical research, but human translation remains incomplete.
Mechanism: Porphyran stimulates the phosphorylation of specific proteins that activate the NF-κB pathway, inducing the production of cytokines such as IL-6, TNF-α, and IFN-γ, all involved in coordinating the immune response. Porphyran separated into fractions on DEAE-chromatography showed an inhibitory effect on nitric oxide (NO) production from LPS-stimulated RAW264.7 cells.
In vivo animal data: A previous investigation explored the immunomodulatory efficacy of porphyran isolated from Porphyra vietnamenis. Oral administration of porphyran (200–500 mg/kg) to Wistar albino rats evoked a significant increase in weights of the thymus and spleen, as well as increased lymphoid organ cellularity.
Evidence strength: Based on in vitro, ex vitro, and in vivo experimental data, immunomodulatory effects of N. yezoensis have been comprehensively discussed. However, although N. yezoensis has shown promising bioactivity in preclinical models, validated clinical data in humans are currently lacking. The evidence at the human clinical level is absent; immunomodulatory claims rest entirely on in vitro and animal model data.
Anti-inflammatory activity is among the pharmacological properties comprehensively discussed for N. yezoensis in the 2025 updated review. The principal proposed mechanism involves porphyran-mediated regulation of macrophage activity and nitric oxide production. The antioxidant activity of dietary compounds, particularly in reducing NO levels released by macrophages, is also recognized as contributing to their anti-inflammatory effects. This anti-inflammatory activity may arise from modulating the synthesis and/or release of NO by macrophages rather than from direct scavenging alone.
Evidence strength: As with immunomodulation, evidence for anti-inflammatory activity from nori is derived from cell culture and animal models. No human clinical trials examining inflammatory biomarkers as primary endpoints following nori supplementation have been published.
Porphyran supplementation significantly decreased apolipoprotein B100 secretion in HepG2 cells through a mechanism partially associated with the suppression of cellular lipid synthesis. This was the first study to elucidate the mechanism for the hypolipidemic effect of porphyran.
Different beneficial effects such as anticancer, antiviral, anticoagulant, hypocholesterolemic, and antioxidant have been demonstrated in preclinical and in vitro seaweed research. Porphyrans have also been found to regulate the gut microbiota during the treatment of metabolic syndrome, suggesting an indirect mechanism for metabolic benefit through the gut-microbiome axis.
Evidence strength: Current evidence for cholesterol-lowering and broader metabolic effects of nori is limited to cell culture and animal studies. No robust human RCTs specifically examining nori's effects on lipid panels have been identified.
Indigestible polysaccharides as dietary fibers provide various beneficial effects, such as lowering of blood cholesterol level and blood pressure, as well as protective effects against infectious and inflammatory diseases. Porphyran in particular has been studied for its prebiotic potential. A comprehensive scientific review published by Kaur and colleagues (2025) synthesized all the data on immunomodulation and intestinal barrier support by porphyran, confirming that porphyran has well-documented immunomodulatory, antioxidant, and prebiotic properties.
Evidence strength: The prebiotic and gut microbiota evidence for nori porphyran is primarily derived from preclinical and mechanistic studies. While this is an active and promising area of research, robust human intervention trials documenting specific effects on the human microbiome from nori consumption are not yet established.
In vitro and in vivo experimental data comprehensively discuss neuroprotective and anti-aging properties of N. yezoensis extracts and bioactive compounds. Specific mechanisms under investigation include the ability of nori-derived compounds to modulate oxidative stress pathways relevant to neurodegeneration, though this work remains at the preclinical stage.
Evidence strength: Entirely preclinical and in vitro. No human data exist for neuroprotective or anti-aging applications.
The most significant benefit of dried seaweed for many people is its iodine content. The thyroid gland uses iodine to produce two hormones, T3 and T4, that regulate metabolism, protein creation, and enzyme activity throughout the body. A few sheets of nori (the kind wrapped around sushi) provide a moderate 50 to 100 micrograms of iodine.
This makes nori a practical dietary source of iodine for populations at risk of deficiency, including those who do not use iodized salt. However, the iodine content of nori is significantly lower than that of brown seaweeds like kombu. In human feeding studies, a much lower iodine concentration of 5.0 µg/g was determined for nori compared to a high iodine concentration of 3,522 µg/g observed in kombu.
The following dosages are reported directly from published studies. They do not represent recommendations.
Generally, high iodine intakes do not cause health problems in most healthy people, but certain groups may be more sensitive to excessive iodine and should limit their intake of seaweed products. These include people with existing thyroid disorders, either hypothyroidism or hyperthyroidism (excess production of thyroid hormones), school-aged children, and infants.
Nori has comparatively lower iodine content than most other commonly consumed seaweeds. The iodine content of nori is generally considered moderate compared to other seaweeds like kombu or wakame. A 5-gram portion of nori provides approximately 50 to 150 µg of iodine according to sources, which remains within acceptable limits for most people.
Both fresh and dried seaweed may contain heavy metals such as arsenic, mercury, cadmium, or lead, depending on the habitat from which they were sourced. Seaweed absorbs these metals when growing in contaminated areas, such as from industry or poor sewage systems.
Cadmium is the primary heavy metal concern specifically associated with nori. Testing of 35 commercial nori samples found cadmium concentrations ranging from 1.23 to 3.63 micrograms per gram, with every sample exceeding 1.2 micrograms per gram. Some samples led to measurable cadmium accumulation in lab models. This does not mean nori is dangerous in normal amounts. A typical nori sheet weighs only 2 to 3 grams, so actual cadmium exposure from a few sheets of sushi wrap or a handful of snack nori is quite small. The concern applies more to people eating large quantities daily over long periods.
On the positive side, nori tends to be much lower in arsenic than brown seaweeds like hijiki, which is the seaweed type most flagged for arsenic contamination. EFSA has assessed seaweed-related heavy metal exposure in European populations. From seaweed consumption, exposure estimates for cadmium in adult consumers are within the range of previous exposure estimates considering the whole diet, while for inorganic arsenic and lead, the exposure estimates represent between 10% and 30% of previous exposures from the whole diet for the adult population. Seaweeds were also identified as important sources of total arsenic that mainly refers, with some exceptions, to organic arsenic.
Current food safety guidelines do not have standards specifically designed for seaweed, which means testing and labeling remain inconsistent across brands.
The bioavailability of B12 from dried versus raw nori remains a documented point of scientific controversy. A discrepancy between raw and dried nori as a source of cobalamin was identified; while the contents of cobalamin homologues in both raw and dried nori were similar by bioassay method, urinary methylmalonic acid excretion increased when human female volunteers were given 40 g of dried nori daily during the test period. This suggested potential interference with B12 utilization by dried nori in that earlier study, in contrast to the 2024 RCT findings with roasted nori. While nori does contain small amounts of active B12, a study of B12-deficient children found that those eating nori showed rising blood levels of the vitamin, yet their blood cell markers of deficiency actually worsened. Children who ate fish or took a B12 supplement improved. So while seaweed contributes trace B12, it is not a dependable replacement for animal sources or supplements.
Nori also contains amphipod allergens that may cause serious allergic reactions, especially in highly sensitized crustacean-allergic people. Individuals with known shellfish or crustacean allergies should exercise caution, as farmed nori can harbor amphipod crustaceans whose proteins may co-occur in commercial nori sheets.
Nori had the lowest salt level among the seaweeds assessed in one assessment of Irish seaweed species, indicating that plain, unseasoned nori is among the lower-sodium seaweed options. However, seasoned nori snacks can contain added salt, oil, sugar, and sometimes shrimp or fish powders; those managing hypertension or allergies should choose unseasoned sheets and read ingredient lists.
No specific pharmacokinetic drug-drug interactions with nori constituents have been established in peer-reviewed clinical literature. The iodine content of nori is a theoretical consideration for individuals taking thyroid medications, particularly levothyroxine, given the sensitivity of thyroid hormone synthesis to iodine flux; those on thyroid medication should keep nori portions consistent from week to week and take thyroid medication on an empty stomach away from high-fiber meals to support absorption. Additionally, the anticoagulant properties attributed to seaweed polysaccharides in preclinical models represent a theoretical consideration for individuals on anticoagulant therapy, though clinical data on this specific interaction are not established.
Health conditions that Nori may help support.
Body systems that Nori may help support.
Go back